A phase II single-arm study of the FGFR inhibitor pemigatinib in patients with metastatic colorectal cancer (mCRC) harboring FGF/FGFR alterations. Durvalumab and tremelimumab plus local tumor ablation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results